HomePeptide dosagesPT-141 (bremelanotide)
PT-141 (bremelanotide) dosage: chart, reported range and vial math
PT-141 (bremelanotide) is injected under the skin as needed, not daily. The Vyleesi label dose is 1.75 mg at least 45 minutes before, with no more than one dose in 24 hours and no more than 8 a month. It is approved in the US for premenopausal women only, and not authorized in Canada.
Legal status
US Approved for one use
Canada Not authorized
Checked 10 Oct 2026What is PT-141 (bremelanotide)?PT-141 (bremelanotide) dosage chart
Reported range, not a label dosePick your vial size. Each row shows the dose in milligrams or micrograms, the volume to draw and the mark on a U-100 syringe.
| Source | Dose | Volume | Syringe units |
|---|---|---|---|
| Reported starting dose | 1 mg | 0.20 mL | 20 units |
| Vyleesi label | 1.75 mg | 0.35 mL | 35 units |
| Reported high end | 2 mg | 0.40 mL | 40 units |
Source The label dose is for Vyleesi as supplied. The other rows are reported use, not a label dose. Vial math is arithmetic.
Which syringe fits each dose
For the 10 mg vial at 5 mg/mL.
| Dose | Volume | Units | 0.3 mL syringe | 0.5 mL syringe | 1 mL syringe |
|---|---|---|---|---|---|
| 1 mg | 0.20 mL | 20 units | Yes | Yes | Yes |
| 1.75 mg | 0.35 mL | 35 units | No | Yes | Yes |
| 2 mg | 0.40 mL | 40 units | No | Yes | Yes |
How long a vial lasts
Whole doses in one vial. The row for the size picked above is marked.
| Vial | 1 mg | 1.75 mg | 2 mg |
|---|---|---|---|
| 10 mg vial | 10 doses | 5 doses | 5 doses |
How to mix a PT-141 (bremelanotide) vial
These steps are for the 10 mg vial picked in the chart. Change the size there and the amounts here change with it.
- Wash your hands. Wipe the stopper of the peptide vial and the water vial with an alcohol swab.
- Draw 2 mL of bacteriostatic water into a syringe.
- Push the needle through the stopper of the peptide vial and let the water run slowly down the glass, not straight onto the powder.
- Swirl the vial gently until the powder is gone. Do not shake it.
- Write the date and 5 mg/mL on the vial, then put it in the fridge.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 10 mg vial | 2 mL | 5 mg/mL |
What PT-141 (bremelanotide) is
Bremelanotide (PT-141) is a synthetic cyclic seven-amino-acid peptide that activates melanocortin receptors. In the US it is sold as Vyleesi, an autoinjector used under the skin as needed by premenopausal women with acquired, generalized hypoactive sexual desire disorder. [1]
Other names: bremelanotide, Vyleesi, BMT.
How it has been given to people: subcutaneous injection (the approved product); intranasal in early trials.
What to know before reading a dose
- The only approved use is in premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label says it is not indicated for men, for postmenopausal women or to enhance sexual performance.
- The label dose is 1.75 mg. The 4 mg, 6 mg and up to 10 mg amounts come from early studies in men and are not label doses.
- Not authorized in Canada. Health Canada has seized unauthorized vials sold as bremelanotide and as PT-141 [9], [10].
- Contraindicated with uncontrolled high blood pressure or known cardiovascular disease.
- In the phase 3 trials 18% of women stopped because of side effects, against 2% on placebo; nausea affected 40%.
Doses on record for PT-141 (bremelanotide)
Every dose below was given in a human study or printed on an approved label, and each links to its source. Doses set by body weight are left that way.
| From | Where it was used | Dose | How often | For how long | Source |
|---|---|---|---|---|---|
| Label | Vyleesi US label, subcutaneous injection in the abdomen or thigh by prefilled autoinjector | 1.75 mg | as needed, at least 45 minutes before anticipated sexual activity; no more than one dose within 24 hours; more than 8 doses a month not recommended | stop after 8 weeks if there is no improvement | [1] |
| Human study | Phase 3 RECONNECT trials (studies 301 and 302), subcutaneous injection | 1.75 mg | as needed | 24 weeks | [3] |
| Human study | Phase 2b dose-finding trial, self-administered subcutaneous injection | 0.75 mg | as desired | 12 weeks | [4] |
| Human study | Phase 2b dose-finding trial, self-administered subcutaneous injection | 1.25 mg | as desired | 12 weeks | [4] |
| Human study | Phase 2b dose-finding trial, self-administered subcutaneous injection | 1.75 mg | as desired | 12 weeks | [4] |
| Human study | Phase 1 study in men, subcutaneous injection, full range tested (not an approved use) | 0.3 to 10 mg (range of single doses) | single doses | not stated in the abstract | [5] |
| Human study | Crossover study in men with erectile dysfunction and an inadequate response to sildenafil, subcutaneous injection (not an approved use) | 4 mg | single doses in a crossover design | not stated in the abstract | [5] |
| Human study | Crossover study in men with erectile dysfunction and an inadequate response to sildenafil, subcutaneous injection (not an approved use) | 6 mg | single doses in a crossover design | not stated in the abstract | [5] |
What the evidence shows
Each finding is tagged by the kind of study it comes from. Human trials are listed first.
Randomized human trial
In two identical 24-week phase 3 trials, bremelanotide raised the sexual desire score more than placebo (by 0.30 and 0.42 points) and lowered the distress score more than placebo (by 0.37 and 0.29 points). [3]
Randomized human trial
On the label's own figures the desire score, which runs from 1.2 to 6.0, rose by a mean 0.5 points (Study 1) and 0.6 points (Study 2) on Vyleesi against 0.2 points on placebo in both. [1]
Randomized human trial
In the 12-week dose-finding trial, the 1.25 mg and 1.75 mg groups pooled gained 0.7 satisfying sexual events a month against 0.2 on placebo. [4]
Randomized human trial
An independent re-analysis of the two phase 3 trials, using the FDA application data, found that far more women stopped the study because of side effects on bremelanotide than on placebo and judged the benefit modest. [7]
Small human study
In healthy men, subcutaneous doses above 1.0 mg produced a statistically significant erectile response, and 4 mg and 6 mg did so in men who responded poorly to sildenafil. This is not an approved use. [5]
Small human study
An early intranasal form produced a significant erectile response in men only at doses above 7 mg; its half-life after nasal dosing was about 1.85 to 2.09 hours. No nasal product was approved. [8]
Human observational study
Of 856 women who finished the phase 3 trials, 684 entered a 52-week open-label extension and 272 completed it. No new safety signals were reported. [6]
Side effects and warnings
Reported in human studies or on a label:
- Nausea is the most common side effect: 40% of women on Vyleesi in the phase 3 trials. It usually starts within an hour of the dose and lasts about two hours. [1]
- The label's list of the most common reactions. [1]
- Blood pressure rises and heart rate falls for a time after each dose, usually returning to baseline within 12 hours. [1]
- Dark patches of skin (face, gums, breasts) were reported in 1% of women using up to 8 doses a month, and in 38% of people dosed daily for 8 days. They did not always fade after stopping. [1]
- In the phase 3 trials 18% of women on Vyleesi stopped because of side effects, against 2% on placebo. [1]
- One case of acute hepatitis was reported in the open-label extension; liver tests returned to normal 4 months after stopping. [1]
From the label
- Contraindicated in uncontrolled high blood pressure or known cardiovascular disease. [1]
- No more than one dose within 24 hours, because doses close together may add to the blood pressure effect. [1]
- More than 8 doses a month is not recommended. [1]
- Not indicated for men or for postmenopausal women. [1]
- Not indicated to enhance sexual performance. [1]
- Interaction: avoid with naltrexone taken by mouth for alcohol or opioid addiction, because Vyleesi may sharply lower naltrexone levels. [1]
- Interaction: it may slow stomach emptying and reduce absorption of medicines taken by mouth. [1]
- Pregnancy: use effective contraception and stop if pregnancy is suspected. [1]
- Stop after 8 weeks if symptoms have not improved. [1]
- Taking ondansetron beforehand did not reduce nausea in a study of 228 women and is not recommended. [1]
Storage
Store at or below 25 C (77 F). Do not freeze. Protect from light. [1]
PT-141 (bremelanotide) dosage questions
How many units is 1.75 mg of PT-141 (bremelanotide) from a 10 mg vial?
Mixed with 2 mL of bacteriostatic water, a 10 mg vial is 5 mg/mL. 1.75 mg is 0.35 mL, which is 35 units on a U-100 syringe.
How much water goes in a 10 mg PT-141 (bremelanotide) vial?
2 mL gives 5 mg/mL. At that strength the doses in the chart sit at 20, 35, 40 units on a U-100 syringe.
How many doses are in a 10 mg vial?
Whole doses in one vial: 10 at 1 mg, 5 at 1.75 mg, 5 at 2 mg.
Is PT-141 (bremelanotide) approved in the US?
FDA approved as Vyleesi (NDA 210557, approved 2019-06-21) for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label says it is not indicated for men or for postmenopausal women.
Is PT-141 (bremelanotide) authorized in Canada?
No bremelanotide product is in Health Canada's Drug Product Database. Health Canada has named bremelanotide and PT-141 among seized unauthorized injectable peptide drugs.
What is the half-life of PT-141 (bremelanotide)?
About 2.7 hours after a single subcutaneous dose (the label gives a range of 1.9 to 4.0 hours). Blood levels peak at about 1 hour.
What does the Vyleesi label say about dose?
1.75 mg under the skin of the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. No more than one dose within 24 hours. More than 8 doses a month is not recommended. Stop after 8 weeks if there is no improvement.
Sources
Each one was opened on 10 Oct 2026 and matched to the line it supports.
- Cosette Pharmaceuticals, Inc. VYLEESI (BREMELANOTIDE) INJECTION [COSETTE PHARMACEUTICALS, INC.] 2025. api.fda.gov.
- US Food and Drug Administration Drugs@FDA (openFDA drugsfda endpoint): VYLEESI, NDA210557 2026. api.fda.gov.
- Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019. PubMed 31599840. Trial NCT02333071; NCT02338960.
- Clayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 2016. PubMed 27181790. Trial NCT01382719.
- Rosen RC et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004. PubMed 14999221.
- Simon JA et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019. PubMed 31599847. Trial NCT02333071; NCT02338960.
- Spielmans GI Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. J Sex Res 2021. PubMed 33678061.
- Diamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004. PubMed 14963471.
- Health Canada Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks 2025. recalls-rappels.canada.ca.
- Health Canada Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks 2025. recalls-rappels.canada.ca.
- Health Canada Drug Product Database (API): active ingredient lookup for BREMELANOTIDE and brand lookup for VYLEESI 2026. health-products.canada.ca.
Looked for and not found
- No Health Canada authorization: ingredient and brand lookups in the Drug Product Database returned nothing.
- No approved dose for men or for postmenopausal women. The label says it is not indicated for either.
- No approved nasal or oral product. Intranasal amounts from the early trial are not listed as dose rows because the abstract gives only a threshold (above 7 mg).
- How long one dose keeps working: the label says the duration of efficacy after each dose is unknown.
- Numbers of men in the phase 1 and sildenafil-failure studies are not given in the abstract.
- Bremelanotide is not named in the WADA 2026 Prohibited List. Whether any general class of the list covers it was not determined.
Change log
10 Oct 2026Page published. 11 sources checked. Vial math added for the 10 mg vial.
Related
Kisspeptin-10 dosageGonadorelin dosageTestagen dosageHCG dosageHMG dosage10 mg vialWhat PT-141 (bremelanotide) isHormonal and sexual healthPeptide dosage chartDosage calculator
DosageFacts is an information site. It is not medical advice. Talk to a licensed professional before using any medication.